Home › Companies › ULTRAGENYX PHARMACEUTICAL INC. › 2024-2025

ULTRAGENYX PHARMACEUTICAL INC. 2024-2025 Proxy Voting Records

Compiled from SEC Form N-PX filings and ULTRAGENYX PHARMACEUTICAL INC.’s Form 8-K, filed May 19, 2025 (Item 5.07 on EDGAR). Page generated October 14, 2026.

5Ballot items
346Asset managers
1,976Fund votes
May 15, 2025Meeting date

Results at a glance

Meeting of May 15, 2025: 5 items on ULTRAGENYX PHARMACEUTICAL INC.’s Form 8-K, filed May 19, 2025: 2 approved · 3 without a stated outcome.

Material dissent

Proposal 2: Approval of the Second A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the Second A&R 2023 Plan. The… 67% of votes cast Approved Under 80%
4. Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company's stockholders voted, on an advisory… 68% of votes cast Outcome not stated Say-on-pay under 70%

Material dissent: a director nominee under 80% of the votes cast, say-on-pay under 70%, any other item the board put forward under 80%, or a shareholder proposal with more than 50%, on the company’s own Form 8-K tally. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Explore ULTRAGENYX PHARMACEUTICAL INC. in the interactive database Compare manager voting policies

Official 2024-2025 meeting results reported by ULTRAGENYX PHARMACEUTICAL INC.

These tallies are ULTRAGENYX PHARMACEUTICAL INC.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed May 19, 2025 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

ULTRAGENYX PHARMACEUTICAL INC. — official shareholder meeting results, meeting held May 15, 2025
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Support (of votes cast)	Reported outcome	Voting standard
Elect Director: Matthew K. Fust	69,816,485	--	--	11,374,883	5,318,239	86%	Not verified	—
Elect Director: Amrit Ray, M.D.	77,323,215	--	--	3,868,153	5,318,239	95%	Not verified	—
Proposal 2: Approval of the Second A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the Second A&R 2023 Plan. The votes on Proposal 2 were as follows:	54,269,114	26,890,355	31,899	--	5,318,239	67%	Approved	—
Proposal 3: Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal yea	84,295,941	2,188,722	24,894	--	--	97%	Approved	—
4. Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company's stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pays to its "named executive officers" as described	55,098,060	26,074,207	19,101	--	5,318,239	68%	Not verified	—

Source: ULTRAGENYX PHARMACEUTICAL INC., Form 8-K, filed with the SEC on May 19, 2025 — read the filing on EDGAR.

How asset managers voted at the ULTRAGENYX PHARMACEUTICAL INC. 2024-2025 meeting

Each item below shows how the 346 asset managers that disclosed a ULTRAGENYX PHARMACEUTICAL INC. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report.

1. Elect Director: Amrit Ray, M.D.

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 6 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%

FOR: 77,323,215WITHHELD: 3,868,153

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Nominees: Amrit Ray, M.D.

ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Amrit Ray, M.D.”): 77,323,215 for, 3,868,153 withheld, per its Form 8-K filed May 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 95% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 31,761,945 for, 1,217,208 withheld, 57,789 abstained.

FOR

FOR: 31,761,945ABSTAIN: 57,789WITHHOLD: 1,217,208

Largest asset managers voting on “Nominees: Amrit Ray, M.D.” at ULTRAGENYX PHARMACEUTICAL INC., 2024-2025
Asset manager	For	Abstain	Withheld	Vote
Vanguard	11,411,537	1	0	For
T. Rowe Price	2,407,537	0	34,900	For
BlackRock	2,349,212	0	0	For
Fidelity	2,171,483	0	0	For
Federated Hermes	2,049,800	0	0	For
Legg Mason	1,319,888	0	0	For
State Street	1,175,712	0	0	For
Invesco	959,477	0	0	For
ACAP Strategic Fund	826,698	0	0	For
TOUCHSTONE FUNDS GROUP TRUST	801,796	0	0	For
Charles Schwab	589,558	0	0	For
TIAA	458,810	0	0	For
Aberdeen	441,169	0	0	For
MFS	441,090	0	0	For
Putnam	346,835	0	0	For
AllianceBernstein	0	0	345,774	Withhold
Loomis Sayles	326,789	0	0	For
AB DISCOVERY GROWTH FUND, INC.	0	0	316,731	Withhold
Goldman Sachs	285,943	0	0	For
John Hancock	253,420	0	0	For
BNY Mellon	245,907	0	0	For
Advantage Advisers Xanthus Fund, L.L.C.	241,221	0	0	For
Brighthouse	171,101	0	13,308	Mixed
Principal	0	0	181,774	Withhold
DRIEHAUS MUTUAL FUNDS	177,893	0	0	For

Showing the 25 largest of 99 asset managers. See all 99 in the interactive database.

2. Elect Director: Matthew K. Fust

Outcome not verifiedDIRECTOR ELECTIONSReported outcome: Not verified

Combines 5 wordings of this item as funds reported it.

86% Majority: yes · of votes cast

FOR 86%WITHHELD

FOR: 69,816,485WITHHELD: 11,374,883

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Nominees: Matthew K. Fust

ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Elect Director: Matthew K. Fust”): 69,816,485 for, 11,374,883 withheld, per its Form 8-K filed May 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 86% of votes cast — FOR ÷ (FOR + WITHHELD); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 28,706,489 for, 4,272,662 withheld, 57,790 abstained.

FOR

FOR: 28,706,489ABSTAIN: 57,790WITHHOLD: 4,272,662

Largest asset managers voting on “Nominees: Matthew K. Fust” at ULTRAGENYX PHARMACEUTICAL INC., 2024-2025
Asset manager	For	Abstain	Withheld	Vote
Vanguard	11,411,536	2	0	For
T. Rowe Price	2,407,537	0	34,900	For
BlackRock	2,349,212	0	0	For
Fidelity	2,171,483	0	0	For
Federated Hermes	2,049,800	0	0	For
Legg Mason	1,319,888	0	0	For
State Street	3,358	0	1,172,354	Withhold
Invesco	0	0	959,477	Withhold
ACAP Strategic Fund	826,698	0	0	For
TOUCHSTONE FUNDS GROUP TRUST	801,796	0	0	For
Charles Schwab	589,558	0	0	For
TIAA	458,810	0	0	For
Aberdeen	441,169	0	0	For
MFS	0	0	441,090	Withhold
Putnam	346,835	0	0	For
AllianceBernstein	0	0	345,774	Withhold
Loomis Sayles	326,789	0	0	For
AB DISCOVERY GROWTH FUND, INC.	0	0	316,731	Withhold
Goldman Sachs	0	0	285,943	Withhold
John Hancock	253,420	0	0	For
BNY Mellon	245,907	0	0	For
Advantage Advisers Xanthus Fund, L.L.C.	241,221	0	0	For
Brighthouse	171,101	0	13,308	Mixed
Principal	0	0	181,774	Withhold
DRIEHAUS MUTUAL FUNDS	177,893	0	0	For

Showing the 25 largest of 99 asset managers. See all 99 in the interactive database.

3. Proposal 2: Approval of the Second A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the Second…

Official result Fund totals may overlapCOMPENSATIONReported outcome: Approved

Combines 3 wordings of this item as funds reported it.

67% Approved · of votes cast

FOR 67%AGAINST

FOR: 54,269,114AGAINST: 26,890,355

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Approval of the Second Amended and Restated 2023 Incentive Plan.

ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Proposal 2: Approval of the Second A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the Second A&R 2023 Plan. The votes on Proposal 2 were as follows:”): 54,269,114 for, 26,890,355 against — passed, per its Form 8-K filed May 19, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 2 – Approval of the Second A&R 2023 Plan At the Annual Meeting, the Company's stockholders approved the Second A&R 2023 Plan.”
Support: 67% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 97 asset managers voting on “Approval of the Second Amended and Restated 2023 Incentive Plan.” at ULTRAGENYX PHARMACEUTICAL INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	11,411,531	7	0	For
T. Rowe Price	2,407,537	34,900	0	For
BlackRock	2,349,212	0	0	For
Fidelity	1,573,548	597,935	0	Mixed
Federated Hermes	2,049,800	0	0	For
Legg Mason	1,319,888	0	0	For
State Street	2,256	1,173,456	0	Against
Invesco	959,477	0	0	For
ACAP Strategic Fund	0	826,698	0	Against
TOUCHSTONE FUNDS GROUP TRUST	801,796	0	0	For
Charles Schwab	589,558	0	0	For
TIAA	0	458,810	0	Against
Aberdeen	0	441,169	0	Against
MFS	0	441,090	0	Against
Putnam	0	346,835	0	Against
AllianceBernstein	345,774	0	0	For
Loomis Sayles	326,789	0	0	For
AB DISCOVERY GROWTH FUND, INC.	316,731	0	0	For
Goldman Sachs	0	285,943	0	Against
John Hancock	26,489	226,931	0	Mixed
BNY Mellon	0	245,907	0	Against
Advantage Advisers Xanthus Fund, L.L.C.	0	241,221	0	Against
Brighthouse	168,874	2,227	13,308	Mixed
Principal	181,774	0	0	For
DRIEHAUS MUTUAL FUNDS	0	177,893	0	Against

Fund voting reports, all 97 managers: 26,064,450 for, 6,921,569 against, 13,308 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 2 asset managers voting on “Approval of the Second Amended and Restated 2023 Incentive Plan.” at ULTRAGENYX PHARMACEUTICAL INC., 2024-2025
Asset manager	For	Against	Abstain	Withheld	Vote
First Light Asset Management, LLC	608,456	0	0	0	For
UNITED CAPITAL FINANCIAL ADVISORS, LLC	0	782	0	0	Against

Institutional-manager reports, all 2 managers: 608,456 for, 782 against.

4. 4. Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company's stockholders…

Outcome not verified Fund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Not verified

Combines 11 wordings of this item as funds reported it.

68% Majority: yes · of votes cast

FOR 68%AGAINST

FOR: 55,098,060AGAINST: 26,074,207

Details: description as filed, official tally, votes by 345 asset managers

Description as filed by funds: Advisory (non-binding) vote to approve the compensation of our named executive officers.

ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“4. Advisory (Non-Binding) Vote to Approve Executive Compensation At the Annual Meeting, the Company's stockholders voted, on an advisory basis, in favor of a resolution approving the compensation the Company pays to its ”): 55,098,060 for, 26,074,207 against, per its Form 8-K filed May 19, 2025 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Reported outcome: not verified — the filing’s own statement of the outcome could not be identified for this item.
Support: 68% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports: 99 asset managers voting on “Advisory (non-binding) vote to approve the compensation of our named executive officers.” at ULTRAGENYX PHARMACEUTICAL INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	10,669,450	742,088	0	Mixed
T. Rowe Price	2,407,537	34,900	0	For
BlackRock	2,349,212	0	0	For
Fidelity	2,171,483	0	0	For
Federated Hermes	2,049,800	0	0	For
Legg Mason	0	1,319,888	0	Against
State Street	1,173,453	2,259	0	For
Invesco	959,477	0	0	For
ACAP Strategic Fund	0	826,698	0	Against
TOUCHSTONE FUNDS GROUP TRUST	801,796	0	0	For
Charles Schwab	589,558	0	0	For
TIAA	0	458,810	0	Against
Aberdeen	0	441,169	0	Against
MFS	0	441,090	0	Against
Putnam	346,835	0	0	For
AllianceBernstein	0	345,774	0	Against
Loomis Sayles	326,789	0	0	For
AB DISCOVERY GROWTH FUND, INC.	0	316,731	0	Against
Goldman Sachs	0	285,943	0	Against
John Hancock	118,618	134,802	0	Mixed
BNY Mellon	5,516	240,391	0	Against
Advantage Advisers Xanthus Fund, L.L.C.	0	241,221	0	Against
Brighthouse	168,874	2,227	13,308	Mixed
Principal	112,206	69,568	0	Mixed
DRIEHAUS MUTUAL FUNDS	0	177,893	0	Against

Fund voting reports, all 99 managers: 25,653,387 for, 7,384,946 against, 13,308 abstained. Showing the 25 largest; see all in the interactive database.

Institutional-manager reports: 275 asset managers voting on “Advisory (non-binding) vote to approve the compensation of our named executive officers.” at ULTRAGENYX PHARMACEUTICAL INC., 2024-2025
Asset manager	For	Against	Vote
T. Rowe Price	3,173,154	54,975	For
BlackRock	2,996,672	28,305	For
SANDS CAPITAL MANAGEMENT, LLC	2,854,891	0	For
State Street	2,402,213	43,322	For
Clearbridge Investments, LLC	0	2,230,833	Against
Wellington	2,073,296	0	For
Federated Hermes	2,049,804	0	For
SUVRETTA CAPITAL MANAGEMENT, LLC	0	2,001,935	Against
ADAGE CAPITAL PARTNERS GP, L.L.C.	1,983,682	0	For
RTW INVESTMENTS, LP	1,707,402	0	For
GEODE CAPITAL MANAGEMENT, LLC	1,631,693	0	For
Rock Springs Capital Management LP	1,371,091	0	For
Deep Track Capital, LP	1,350,000	0	For
PICTET ASSET MANAGEMENT SA	0	1,245,699	Against
Point72	0	1,203,546	Against
AllianceBernstein	0	1,139,433	Against
Invesco	1,088,217	0	For
BNP Paribas Asset Management Holding S.A.	0	1,068,334	Against
Alyeska Investment Group, L.P.	0	899,044	Against
Two Sigma	0	881,261	Against
Frazier Life Sciences Management, L.P.	830,915	0	For
Avoro Capital Advisors LLC	830,000	0	For
Candriam S.C.A.	0	728,017	Against
ALKEON CAPITAL MANAGEMENT LLC	0	654,668	Against
First Light Asset Management, LLC	608,456	0	For

Institutional-manager reports, all 275 managers: 34,853,394 for, 19,363,589 against, 1,380 not voted. Showing the 25 largest; see all in the interactive database.

5. Proposal 3: Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's…

Official resultAUDIT-RELATEDReported outcome: Approved

Combines 4 wordings of this item as funds reported it.

97% Approved · of votes cast

FOR 97%

FOR: 84,295,941AGAINST: 2,188,722

Details: description as filed, official tally, votes by 99 asset managers

Description as filed by funds: Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025.

ULTRAGENYX PHARMACEUTICAL INC.’s own tally for this item (“Proposal 3: Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accountin”): 84,295,941 for, 2,188,722 against — passed, per its Form 8-K filed May 19, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal No. 3 – Ratification of Selection of Independent Registered Accounting Firm At the Annual Meeting, the Company's stockholders ratified the selection of Ernst & Young LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025.”
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 99 asset managers below reported 33,011,107 for, 12,527 against, 13,308 abstained.

FOR

FOR: 33,011,107AGAINST: 12,527ABSTAIN: 13,308

Largest asset managers voting on “Ratification of the selection of Ernst & Young LLP as our independent registered public accounting firm for th” at ULTRAGENYX PHARMACEUTICAL INC., 2024-2025
Asset manager	For	Against	Abstain	Vote
Vanguard	11,411,538	0	0	For
T. Rowe Price	2,442,437	0	0	For
BlackRock	2,349,212	0	0	For
Fidelity	2,171,483	0	0	For
Federated Hermes	2,049,800	0	0	For
Legg Mason	1,319,888	0	0	For
State Street	1,175,633	79	0	For
Invesco	959,477	0	0	For
ACAP Strategic Fund	826,698	0	0	For
TOUCHSTONE FUNDS GROUP TRUST	801,796	0	0	For
Charles Schwab	589,558	0	0	For
TIAA	458,810	0	0	For
Aberdeen	441,169	0	0	For
MFS	441,090	0	0	For
Putnam	346,835	0	0	For
AllianceBernstein	345,774	0	0	For
Loomis Sayles	326,789	0	0	For
AB DISCOVERY GROWTH FUND, INC.	316,731	0	0	For
Goldman Sachs	285,943	0	0	For
John Hancock	253,420	0	0	For
BNY Mellon	245,907	0	0	For
Advantage Advisers Xanthus Fund, L.L.C.	241,221	0	0	For
Brighthouse	171,101	0	13,308	Mixed
Principal	181,774	0	0	For
DRIEHAUS MUTUAL FUNDS	177,893	0	0	For

Showing the 25 largest of 99 asset managers. See all 99 in the interactive database.

Largest ULTRAGENYX PHARMACEUTICAL INC. shareholders voting in 2024-2025

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 93,903,785 shares outstanding at the time of that meeting.

Fund voting reports: top ULTRAGENYX PHARMACEUTICAL INC. shareholders by shares voted on “Advisory (non-binding) vote to approve the compensation of our named executive officers.”, 2024-2025
#	Asset manager	% of shares outstanding
1	Vanguard	12.15%
2	T. Rowe Price	2.60%
3	BlackRock	2.50%
4	Fidelity	2.31%
5	Federated Hermes	2.18%
6	Legg Mason	1.41%
7	State Street	1.25%
8	Invesco	1.02%
9	ACAP Strategic Fund	0.88%
10	TOUCHSTONE FUNDS GROUP TRUST	0.85%

Institutional-manager reports: top ULTRAGENYX PHARMACEUTICAL INC. shareholders by shares voted on “Advisory (non-binding) vote to approve the compensation of our named executive officers.”, 2024-2025
#	Asset manager	% of shares outstanding
1	T. Rowe Price	3.44%
2	BlackRock	3.22%
3	SANDS CAPITAL MANAGEMENT, LLC	3.04%
4	State Street	2.60%
5	Clearbridge Investments, LLC	2.38%
6	Wellington	2.21%
7	Federated Hermes	2.18%
8	SUVRETTA CAPITAL MANAGEMENT, LLC	2.13%
9	ADAGE CAPITAL PARTNERS GP, L.L.C.	2.11%
10	RTW INVESTMENTS, LP	1.82%

Reported ULTRAGENYX PHARMACEUTICAL INC. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row names its form.

ULTRAGENYX PHARMACEUTICAL INC. holdings and ownership disclosed for the 2024-2025 proxy season
Holder	% outstanding	Disclosure
Vanguard Group	10.65%	13F
BlackRock	6.56%	13F
FMR LLC	3.57%	13G
Emil D. Kakkis, M.D., Ph.D.	3.51%	DEF14A
T. Rowe Price	3.43%	13F
State Street	2.79%	13F
Wellington Management	2.61%	13F
Geode Capital	1.75%	13F
Invesco	1.29%	13F
Point72	1.04%	13F

Percentages above are of 93,903,785 shares outstanding, as reported by ULTRAGENYX PHARMACEUTICAL INC. on its Form 10-Q dated March 31, 2025 (see the filing on EDGAR). This is the count contemporaneous with the 2024-2025 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from ULTRAGENYX PHARMACEUTICAL INC.’s 10-Q dated March 31, 2025. This page is a static snapshot rebuilt weekly on October 14, 2026; a live search always shows the current data.

At ULTRAGENYX PHARMACEUTICAL INC.'s shareholder meeting held May 15, 2025, in the 2024-2025 proxy season, 346 asset managers reported how they voted on 5 ballot items in their SEC Form N-PX filings, covering 1,976 separate fund positions. On the most widely held item on that ballot — Advisory (non-binding) vote to approve the compensation of our named executive officers. — FOR was 68% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: ULTRAGENYX PHARMACEUTICAL INC.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on May 19, 2025.

ULTRAGENYX PHARMACEUTICAL INC. proxy season coverage: 2023-2024 · 2024-2025 (this page) · 2025-2026.

Download data (CSV): ballot items · votes by manager · column guide.